Comparison of nanOss Cervical IBF System to C-Plus PEEK IBF Device With Autograft

RTI Surgical11 enrolled

Overview

This is a post-market, prospective, randomized clinical investigation to evaluate the performance of the nanOss Cervical Interbody Fusion (IBF) device with nanOss Bioactive Bone Void Filler for the treatment of cervical disc disease. A secondary objective is to compare the performance of the nanOss Cervical IBF Device and nanOss Bioactive Bone Void Filler with the performance of the C-Plus PEEK IBF Device with autograft. This study will enroll 40 patients at one (1) site. After subjects have signed an informed consent, they will be randomly assigned to either the nanOss Cervical IBF device arm or the C-Plus PEEK IBF Device. Patients will complete the preoperative visit and examinations. Patients will be evaluated at discharge, six (6) weeks, three (3) months, six (6) months, and twelve (12) months. Patients will be evaluated at twenty-four (24) months post-operatively if they have not demonstrated fusion at the 12 month time point.

The nanOss Cervical Interbody Fusion Device is CE-marked for single level intervertebral body fusion from C3 to T1 for the treatment of cervical disc disease. The nanOss IBF device is designed to be used as one device per level, with graft material and supplemental fixation. nanOss BABone Void Filler is a resorbable porous calcium phosphate bone void filler for use as a bone graft substitute or bone void filler. It is CE marked for use as a bone void filler in the spine, and it is to be re-hydrated with Bone Marrow Aspirate (BMA) alone, or a mixture of the patient's BMA and autograft. The C-Plus PEEK IBF Device is indicated for use in skeletally mature adults at one level in the cervical spine, from C3 to T1, for the treatment of cervical disc disease. The device is to be used in patients who have had six weeks of non-operative treatment. Autogenous bone graft is placed within the central cavity of the C-Plus PEEK IBF Device. The SlimFuse Cervical Plate System components are titanium alloy plates and screws designed to temporarily provide resistance to flexion, extension, lateral bending and axial rotation with strength and stiffness in the cervical spine (C2-C7) in order to promote cervical fusion. The anterior approach should be used when implanting the SlimFuse Cervical Plate System. The primary goal of this study is to evaluate the outcomes between nanOss Cervical IBF Device and C-Plus PEEK IBF Device. The primary endpoint will be objectively determined via x-rays and CT scan to assess fusion. Secondary endpoints will include subjective patient scores for neck and arm pain and quality of life along with analysis of the proportion of patients who experience a treatment failure.

Study Type

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Is at least 21 years of age and skeletally mature. 2. Must have cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies) at one level in the cervical spine between C3 to T1. 3. Must have completed a minimum of six weeks of unsuccessful conservative, non- operative care or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment 4. Has pre-operative objective evidence of primary diagnosis confirmed by appropriate imaging studies (AP/LAT/FLX/EXT X-rays \& a recent MRI) 5. Is willing and able to comply with all clinical investigation visits and procedures including screening treatment procedures, post-operative management, the follow-up schedule and completion of forms or questionnaires. 6. Is able to understand and sign the informed consent document Exclusion Criteria: 1. Requires fusion at more than one level 2. Has had prior fusion at the level to be treated. 3. Has a metabolic or systemic bone disorder. 4. Has a disease that significantly inhibits bone healing (i.e., severe osteoporosis, osteomalacia, Paget's disease) 5. Has a systemic or local infection (active or latent) 6. Has acute or chronic infections in the surgical area (i.e., soft tissue infections; inflammatory, bacterial bone disorders, osteomyelitis) 7. chronic use of steroids, other than episodic use or inhaled corticosteroids 8. has any significant general illness (i.e. tested positive for HIV, Hepatitis B or Hepatitis C, has active metastatic cancer of any type, uncontrolled diabetes Type I, dialysis dependent renal failure, symptomatic liver disease) 9. has a mental or physical condition that would limit the ability to comply with study requirements or would preclude accurate evaluation. 10. Is immunocompromised or being treated with immunosuppressive agents (including chemotherapy or radiation treatment). 11. has documented allergies to hydroxyapatite or porcine collagen, PEEK, titanium, titanium alloy or tantalum. 12. currently pregnant, or interested in becoming pregnant during the clinical investigation follow-up 13. is a smoker 14. is a prisoner 15. is currently involved in another drug or device clinical investigation that may confound the clinical investigation data.

Outcomes

Primary Outcomes

Number of patients demonstrating fusion at 12 months post-operatively

Fusion is defined as the presence of bridging bone between adjacent endplates of the involved motion segment, AND ≤ 2º total angular motion from flexion to extension, AND \< 1.25 mm translational motion.

Time frame: 12 months

Secondary Outcomes

Scores on the Neck Disability Index Questionnaire

Time frame: 12 months

Pain on the Visual Analog Scale

Time frame: 12 months

Adverse Events

Serious device related adverse events.

Time frame: 12 months

Score on the EQ-5D Health Outcomes Survey

Time frame: 12 months

Disc Height in millimetres

Time frame: 12 months

Device Migration in millimetres

Time frame: 12 months

Device Subsidence in millimetres

Time frame: 12 months

Score on the RAND 36 item questionnaire

Time frame: 12 months

Proportion of patients with subsequent surgical intervention

Time frame: 12 months

Comparison of nanOss Cervical IBF System to C-Plus PEEK IBF Device With Autograft

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes